Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Multi-Center Safety and Efficacy Study of Co-Administration of Tesofensine/Metoprolol for 12 Weeks in Adult and Adolescent Patients With Prader-Willi Syndrome (PWS), Followed by Two Open Label 12 Weeks Extension Periods for Adolescent Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Metoprolol/tesofensine (Primary)
- Indications Prader-Willi syndrome
- Focus Therapeutic Use
- Sponsors Saniona
- 07 Feb 2020 Status changed from recruiting to completed.
- 17 Jan 2020 This trial is Completed (Global End Date: 22 Jul 2019), according to European Clinical Trials Database record.
- 13 May 2019 According to a Saniona media release, ongoing open label study has extended in both Czech Republic and Hungary, and last extension of the study will be completed in July 2019.